Altered Gut Microbial Fermentation and Colonization with Methanobrevibacter smithii in Renal Transplant Recipients

Knobbe, Tim J.; Douwes, Rianne M.; Kremer, Daan; Swarte, J Casper; Eisenga, Michele F.; Gomes-Neto, António W; Londen, Marco van; Peters, Frans; Blokzijl, Hans; Nolte, Ilja M.; Hendriks, W.H.; Harmsen, Hermie J. M.; Bakker, Stephan J. L.

doi:10.3390/jcm9020518

Cited by 7 publications

(4 citation statements)

References 49 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This division was based on the participant's microbiota, showing a signature composition indicating the presence of methane-producing bacteria in the host. Our results confirm earlier reports on the methane production being very personalized, with some individuals producing methane while in others methane presence is not detectable; a trait largely related to health (Ghoshal et al, 2016 ; Knobbe et al, 2020 ).…”

Section: Discussionsupporting

confidence: 92%

Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota

Liu

Sadabad

Gabarrini

et al. 2022

Antioxidants & Redox Signaling

Self Cite

View full text Add to dashboard Cite

Aims: We performed a randomized, placebo-controlled trial, RIBOGUT, to study the effect of 2 weeks supplementation with either 50 or 100 mg/d of riboflavin on (i) Faecalibacterium prausnitzii abundance, (ii) gut microbiota composition, (iii) short-chain fatty acid (SCFA) profiles, and (iv) the satiety and gut hormones. Results: Neither dose of riboflavin, analyzed separately, impacted the abundance of F. prausnitzii , and only minor differences in SCFA concentrations were observed. However, combining the results of the 50 and 100 mg/d groups showed a significant increase in butyrate production. While the gut bacterial diversity was not affected by riboflavin supplementation, the complexity and stability of the bacterial network were enhanced. Oral glucose tolerance tests showed a trend of increased plasma insulin concentration and GLP-1 after 100 mg/d supplementation. Innovation: Dietary supplements, such as vitamins, promote health by either directly targeting host physiology or indirectly via gut microbiota modulation. Here, we show for the first time that riboflavin intervention changes the activity of the microbiota. The butyrate production increased after intervention and although the composition did not change significantly, the network of microbial interactions was enforced. Conclusion: This RIBOGUT study suggests that oral riboflavin supplementation promotes butyrate production in the absence of major shifts in gut microbiota composition. Identifier: NCT02929459.

show abstract

Section: Discussionsupporting

confidence: 92%

Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota

Liu

Sadabad

Gabarrini

et al. 2022

Antioxidants & Redox Signaling

Self Cite

View full text Add to dashboard Cite

show abstract

“…Methanobrevibacter smithii is the methanogens usually detected in human gut. Evidence indicated a close connection between Methanobrevibacter smithii and dysbiosis of the digestive tract [ 26 – 28 ]. But the abundance of Archaea is different in population.…”

Section: Discussionmentioning

confidence: 99%

Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients

Chu

Cao

et al. 2022

BMC Microbiol

View full text Add to dashboard Cite

Background Currently, few studies focus on the association between gut microbiota and systemic lupus erythematosus (SLE), and much less studies consider the effect of drug usage. Proton pump inhibitors (PPIs) are commonly used to treat drug-related gastrointestinal damage in SLE patients. Therefore, the purpose of this study is to examine the gut microbiota of SLE patients using PPIs. Methods Fecal samples from 20 SLE patients with PPIs (P-SLE), 20 SLE patients without PPIs (NP-SLE) and 17 healthy controls (HCs) were obtained. The structure of the bacterial community in the fecal samples was analyzed by 16S rRNA gene sequencing. Redundancy analysis (RDA) was performed to observe the relationship between clinical variables and microbiome composition in P-SLE and NP-SLE patients. Based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, functional capabilities of microbiota were estimated. Network analysis was performed to analyze the association of metabolic pathway alterations with altered gut microbiota in P-SLE and NP-SLE patients. Results P-SLE patients exhibited increased alpha-diversity and an altered composition of the gut microbiota compared with NP-SLE patients. The alpha-diversity of NP-SLE patients was significantly lower than HCs but also of P-SLE patients, whose alpha-diversity had become similar to HCs. Compared with NP-SLE patients, the relative abundances of Lactobacillus, Roseburia, Oxalobacter, and Desulfovibrio were increased, while those of Veillonella, Escherichia, Morganella, Pseudomonas and Stenotrophomonas were decreased in P-SLE patients. RDA indicated that PPI use was the only significant exploratory variable for the microbiome composition when comparing SLE patients. KEGG analysis showed that 16 metabolic pathways were significantly different between NP-SLE and P-SLE patients. These metabolic pathways were mainly associated with changes in Escherichia, Roseburia, Stenotrophomonas, Morganella and Alipipes as determined by the network analysis. Conclusions PPI use is associated with an improved microbiome composition of SLE patients as it 1) increases alpha-diversity levels back to normal, 2) increases the abundance of various (beneficial) commensals, and 3) decreases the abundance of certain opportunistic pathogenic genera such as Escherichia. Validation studies with higher patient numbers are however recommended to explore these patterns in more detail.

show abstract

“…According to the United States Renal Data System (USRDS 2021), 130,400 people were newly diagnosed with end-stage renal disease (ESRD) in 2019, an increase of 2.5% over the previous year. Kidney transplantation (KT) (4)(5)(6)(7)(8) is considered the optimal choice for treating ESRD. The recent introduction of novel immunosuppressive agents has reduced the occurrence of one-year acute rejection (AR) following kidney transplantation (9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

STXBP3 and GOT2 predict immunological activity in acute allograft rejection

Yao

Wang

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAcute allograft rejection (AR) following renal transplantation contributes to chronic rejection and allograft dysfunction. The current diagnosis of AR remains dependent on renal allograft biopsy which cannot immediately detect renal allograft injury in the presence of AR. In this study, sensitive biomarkers for AR diagnosis were investigated and developed to protect renal function.MethodsWe analyzed pre- and postoperative data from five databases combined with our own data to identify the key differently expressed genes (DEGs). Furthermore, we performed a bioinformatics analysis to determine the immune characteristics of DEGs. The expression of key DEGs was further confirmed using the real-time quantitative PCR (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemical (IHC) staining in patients with AR. ROC curves analysis was used to estimate the performance of key DEGs in the early diagnosis of AR.ResultsWe identified glutamic-oxaloacetic transaminase 2 (GOT2) and syntaxin binding protein 3 (STXBP3) as key DEGs. The higher expression of STXBP3 and GOT2 in patients with AR was confirmed using RT-qPCR, ELISA, and IHC staining. ROC curve analysis also showed favorable values of STXBP3 and GOT2 for the diagnosis of early stage AR.ConclusionsSTXBP3 and GOT2 could reflect the immunological status of patients with AR and have strong potential for the diagnosis of early-stage AR.

show abstract

Altered Gut Microbial Fermentation and Colonization with Methanobrevibacter smithii in Renal Transplant Recipients

Cited by 7 publications

References 49 publications

Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota

Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota

Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients

STXBP3 and GOT2 predict immunological activity in acute allograft rejection

Contact Info

Product

Resources

About